Foresite Capital, a venture capital firm that invests in emerging healthcare leaders across all areas of healthcare, has enhanced its team with a new venture partner.
The company’s chief executive officer and managing director, Jim Tananbaum, M.D. said he is eager to add one of the well-regarded scientific workers in pharmaceutical research and development, Molly He, Ph.D. to the team.
Tananbaum credited Dr. He’s considerable history of leadership as an indispensable resource as Foresite Capital continues to increase and broaden its portfolio.
Dr. He’s more than 15 years’ experience takes in her most recent position as senior director at Illumina where she took charge of the company’s global protein reagent improvements.
Previously, she was responsible for protein reagent development at Pacific Biosciences. She also spent 10 years in the pharmaceutical industry directing her attention to drugs which are aimed at cancer and immune diseases.
In addition, she holds more than 20 patents and patent applications and has created and published more than 20 papers.
Dr. He expressed her appreciation in joining a company that has such an incomparable reputation of backing some of healthcare’s most ground-breaking companies.
She said she is privileged to join Foresite Capital’s team and is looking forward to working with them on the next surge of scientific research and drug innovations.
According to Jim Tananbaum, Foresite Capital functions as a collective team that deals with important, unfilled healthcare needs across areas such as therapeutics, diagnostics and services.
An industry leader with more than 25 years’ experience, Tananbaum founded the firm in 2011 and focuses his outlook on strategic and economic possibilities.
He previously co-founded both GelTex Pharmaceuticals and Theravance. He has also led investments in more than 20 healthcare companies including Amira Pharmaceuticals, Amerigroup, Jazz Pharmaceuticals and Healtheon.
Jim Tananbaum was recently recognized for the third consecutive year as one of Forbes’ Midas List of Top Tech Investors.
He was ranked #52 on this year’s list, which ranks the world’s smartest tech investors.
Tananbaum holds an M.D. from Harvard Medical School, an M.S. from MIT an M.B.A. from Harvard Business School and undergraduate degrees from Yale University. Visit his LinkedIn account for more details.
Check out his Crunchbase profile for details.